Meeting Overview - The second meeting of the second supervisory board of Jiangsu Weidao Nano Technology Co., Ltd. was held on August 28, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. Financial Reporting - The supervisory board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's operational management and financial status for the first half of 2025 [2][3]. Fund Management - The board reviewed and approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations and that the funds were stored and used appropriately [3][5]. - The board also approved an adjustment to the amount of raised funds allocated to investment projects, ensuring that this adjustment does not adversely affect the normal use of the funds or the interests of shareholders [5][6]. Cash Management - The company plans to use up to RMB 800 million of temporarily idle raised funds for cash management, investing in safe and liquid financial products while ensuring that this does not conflict with the investment plans [6][7]. Foreign Exchange Risk Management - The supervisory board approved the establishment of a foreign exchange hedging management system to mitigate foreign exchange market risks and authorized the company to engage in foreign exchange hedging activities with a maximum transaction amount of RMB 300 million or equivalent [7].

无锡祥生医疗科技股份有限公司 募集资金管理办法 第一章 总则 第一条 为加强、规范无锡祥生医疗科技股份有限公司(以下简称"公司")募集 资金的管理, 提高募集资金使用效率和效益, 根据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》 《上市公司募集资金监管规则》 《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规 则》(以下简称"《上市规则》")等法律法规和规范性文件以及《无锡 祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 结合公司实际情况, 特制定本办法。 公司的董事、高级管理人员应当勤勉尽责, 确保公司募集资金安全, 不 得操控公司擅自或变相改变募集资金用途。 第五条 公司的控股股东、实际控制人及其他关联人不得占用公司募集资金, 不得利用公司募集资金投资项目(以下简称"募投项目")获取不正当利 益。 公司发现控股股东、实际控制人及其他关联人占用募集资金的, 应当 及时要求归还, 并披露占用发生的原因、对公司的影响、清偿整改方案 及整改进展情况。 第二章 募集资金存储 第七条 公司应当在募集资金到账后一 ...

Meeting Overview - The first session of the Supervisory Board's 24th meeting was held on August 27, 2025, with all five supervisors present, ensuring compliance with legal and regulatory requirements [1]. Financial Reporting - The Supervisory Board approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational results and financial status, adhering to relevant regulations [2]. - The voting results for the semi-annual report were unanimous, with 5 votes in favor [2]. Fund Management - The Board approved the special report on the use of raised funds, affirming that the funds were stored and used in accordance with legal regulations, with no violations or harm to shareholder interests [2]. - The voting results for the fund management report were also unanimous, with 5 votes in favor [2]. Risk Assessment - The Board approved the continuous risk assessment report for the financial company, indicating that it has a valid financial license and a robust internal control and risk management system [3]. - The voting results for the risk assessment report were unanimous, with 5 votes in favor [3]. Asset Impairment - The Board approved the proposal for asset impairment provisions for the first half of 2025, stating that the provisions were made in accordance with accounting standards and reflect the financial situation accurately [4]. - The voting results for the asset impairment proposal were unanimous, with 5 votes in favor [4]. Cash Management - The Board approved the use of temporarily idle raised funds for cash management, ensuring that this does not affect project construction or shareholder interests [5]. - The voting results for the cash management proposal were unanimous, with 5 votes in favor [5].

Group 1 - The third extraordinary meeting of the third Supervisory Board of Shanghai Port Construction (Group) Co., Ltd. was held on August 27, 2025, via teleconference, with all three supervisors present [1][2] - The Supervisory Board approved the company's 2025 semi-annual report and summary, confirming that the financial accounting system is sound and complies with relevant laws and regulations [1][2] - The Supervisory Board also approved the special report on the storage and actual use of raised funds for the first half of 2025, stating that the company adhered to regulations regarding the management of raised funds and fulfilled necessary disclosure obligations [2]

Core Points - The company has established a fundraising management system to enhance the efficiency of fundraising and ensure compliance with relevant laws and regulations [1][2][3] - The funds raised must be used specifically for designated purposes, primarily in the field of technological innovation, to enhance the company's competitiveness and innovation capabilities [2][6] - The board of directors is responsible for monitoring the management and usage of the raised funds to prevent investment risks and ensure the safety of the funds [3][4] Fundraising Management - The company must store the raised funds in a dedicated account approved by the board, and these funds cannot be used for other purposes [3][7] - A tripartite supervision agreement must be signed with the underwriter or independent financial advisor and the commercial bank where the funds are stored within one month of the funds being received [3][8] - The company must disclose any changes in the feasibility or expected returns of fundraising projects promptly [5][9] Fund Usage - The raised funds should primarily be used for the main business and technological innovation, and the company is prohibited from using these funds for financial investments or providing them to related parties [6][10] - If the company plans to replace self-raised funds with raised funds, this must be done within six months after the funds are deposited into the dedicated account [7][11] - The company can manage temporarily idle funds through cash management, ensuring that it does not affect the normal progress of investment plans [8][12] Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board and disclosed to shareholders, especially if it involves new projects or significant changes in existing projects [12][13] - The company must conduct a feasibility analysis for new investment projects to ensure they enhance competitiveness and innovation capabilities [12][20] Oversight and Reporting - The company must provide accurate and complete disclosures regarding the actual use of raised funds and any significant deviations from the investment plan [23][24] - The underwriter or independent financial advisor is responsible for ongoing supervision and must conduct regular checks on the management and usage of the funds [14][15]

Summary of Key Points Core Viewpoint The report outlines the fundraising and usage status of the convertible bonds issued by Zhejiang Dongya Pharmaceutical Co., Ltd., detailing the total amount raised, its allocation, and the management of the funds. Group 1: Fundraising Details - The total amount raised from the convertible bonds is RMB 690 million, with a net amount of RMB 680.1844 million after deducting fees [1]. - The funds were fully received by July 12, 2023, and verified by an accounting firm [1]. Group 2: Fund Usage and Management - As of June 30, 2025, RMB 73.47 million has been used from the raised funds, with an investment income of RMB 0.399 million from financial products [1]. - The company has established four-party supervision agreements with banks and underwriters to ensure proper management of the raised funds [1]. - The balance of the funds in dedicated accounts is RMB 207.1073 million, which includes large deposits and structured deposits [1]. Group 3: Investment Projects - The company has not made any early investments or replacements with the raised funds during the reporting period [3]. - There are no instances of using idle funds to temporarily supplement working capital [5]. - The company plans to extend the timeline for the completion of two key projects to December 2025 due to various industry factors [4]. Group 4: Compliance and Reporting - The company has complied with all regulations regarding the disclosure of fundraising and usage, with no significant issues reported [4]. - There have been no changes to the investment projects funded by the convertible bonds during the reporting period [4].

Core Viewpoint - The company has decided to add "Guangzhou Aokun Food Co., Ltd." and "Guangzhou Aokun Food Co., Ltd. Zengcheng Branch" as implementation entities for the fundraising project related to the construction of its headquarters base, while also adjusting the internal investment structure of the project [1][5]. Fundraising Overview - The company issued 9,500,000 convertible bonds at a face value of RMB 100 each, raising a total of RMB 1,216.25 million, with a net amount of RMB 937.84 million after expenses [1][2]. - As of July 31, 2025, the company has invested RMB 519.14 million in the fundraising projects, with the headquarters base construction project receiving RMB 240.10 million [2][4]. Project Implementation Changes - The headquarters base project aims to enhance production efficiency in the frozen baking sector and consolidate production resources in South China [1][3]. - The addition of the new entities is intended to facilitate the construction of the headquarters base and the transfer of production capacity from other facilities [3][4]. Internal Investment Structure Adjustment - The original production line plans were based on past market demands, which have since changed, prompting the company to optimize its production line layout [3][4]. - The adjusted project is expected to yield an annual production capacity of 104,100 tons of frozen baked goods, with projected revenues of RMB 1,100.30 million in the first year of production [4][5]. Impact on Company Operations - The adjustments are seen as a strategic move to better align with market demands and enhance internal business coordination, ultimately supporting the project's implementation without negatively affecting the company's operations [4][5]. - The changes do not alter the intended use of the raised funds or harm shareholder interests, particularly those of minority shareholders [5][6].

| 证券简称：敏芯股份 公告编号：2025-044 | 证券代码：688286 | | | | --- | --- | --- | --- | | 苏州敏芯微电子技术股份有限公司 | | | | | 项报告 | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 | | | | | 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | 根据《上市公司募集资金监管规则》 | | | | | 《上海证券交易所科创板股票上市规则》 | | | | | 《上 | | | | | 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关文件的规 | | | | | 2025 年半年度募集资金存放与使用情况专项说明如下： | 定，将本公司 | | | | 一、募集资金基本情况 | | | | | （一）实际募集资金金额和资金到账时间 | | | | | 中国证券监督管理委员会于 2023 年 11 月 7 日出具《关于同意苏州敏芯微电子 | | | | | 技术股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕2504 号）， | ...

Fundraising Overview - The company raised a total of RMB 1,283,564,291.24 through a non-public offering of 54,900,098 shares, with a net amount of RMB 1,276,238,913.79 after deducting issuance costs of RMB 7,325,377.45, all funds were received by February 14, 2023 [1][2] Fund Utilization - As of June 30, 2025, the company has utilized RMB 1,160,621,541.60 of the raised funds, with RMB 145,366,012.37 used in the current year, all allocated to fundraising projects [2][4] - The remaining balance in the fundraising account is RMB 149,471,571.45, which includes interest income after deducting bank fees and repayments of loans from the subsidiary [2][3] Fund Management - The company has established a dedicated account management system for the raised funds to ensure compliance with regulations and protect investor interests [2][3] - A tripartite supervision agreement was signed with several banks to manage the dedicated accounts for the raised funds [3] Project Financing - The company approved the use of raised funds to provide loans to its subsidiary, Xinhua Surgical Instruments Co., Ltd., for the expansion of high-end precision minimally invasive surgical instruments production, with a loan limit of RMB 208,725,900 [4] - The company has not used idle funds for temporary working capital or invested in financial products [4] Project Adjustments - The company has made adjustments to the timelines for certain fundraising projects due to delays in procurement, acceptance, and delivery, but these changes do not affect the project implementation entities or investment amounts [4][5] - The company has not changed the investment projects or transferred funds to external parties [4][5] Compliance and Disclosure - The company has complied with the relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [4][5]

证券代码：603061 证券简称：金海通 公告编号：2025-043 天津金海通半导体设备股份有限公司 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》和《上海证券交易所上市公司自律监管指南第 1 号——公告格式》等 有关规定，现将天津金海通半导体设备股份有限公司（以下简称"本公司"或"公司"） 一、 募集资金基本情况 （一）扣除发行费用后的募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2023]83 号文《关于核准天津金海通半导体设 备股份有限公司首次公开发行股票的批复》核准，公司于 2023 年 2 月公开发行人民币 普通股（A 股）股票 15,000,000.00 股，每股发行价为人民币 58.58 元，募集资金总额为 人民币 878,700,000.00 元，根据有关规定扣除发行费用 131,888,125.09 元（不含税）后， 募集资金净额为 746,811,874.91 元，该募集资金已于 2023 ...